FR18C1008I2 - Regime posologique de cladribine pour le traitement de la sclerose en plaques - Google Patents

Regime posologique de cladribine pour le traitement de la sclerose en plaques

Info

Publication number: FR18C1008I2
Authority: FR; France
Prior art keywords: cladribine; treatment; multiple sclerosis; dosage regimen; regimen
Prior art date: 2004-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR18C1008C

Other languages

English (en)

French (fr)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Serono SA

Original Assignee

Merck Serono SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2018-02-14

Publication date

2019-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-02-14 Application filed by Merck Serono SA filed Critical Merck Serono SA

2018-03-30 Publication of FR18C1008I1 publication Critical patent/FR18C1008I1/fr

2019-03-01 Application granted granted Critical

2019-03-01 Publication of FR18C1008I2 publication Critical patent/FR18C1008I2/fr

Status Active legal-status Critical Current

Links

PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title 1
229960002436 cladribine Drugs 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

FR18C1008C 2004-12-22 2018-02-14 Regime posologique de cladribine pour le traitement de la sclerose en plaques Active FR18C1008I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US63866904P	2004-12-22	2004-12-22
EP04106909		2004-12-22
EP05823474A EP1827461B1 (de)	2004-12-22	2005-12-20	Cladribin dosierschema zur behandlung von multipler sklerose
PCT/EP2005/056954 WO2006067141A1 (en)	2004-12-22	2005-12-20	Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number	Publication Date
FR18C1008I1 FR18C1008I1 (de)	2018-03-30
FR18C1008I2 true FR18C1008I2 (fr)	2019-03-01

Family

ID=36227798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR18C1008C Active FR18C1008I2 (fr)	2004-12-22	2018-02-14	Regime posologique de cladribine pour le traitement de la sclerose en plaques

Country Status (25)

Country	Link
US (2)	US7713947B2 (de)
EP (7)	EP2275110B1 (de)
JP (7)	JP5795456B2 (de)
KR (1)	KR20070091662A (de)
AR (1)	AR052830A1 (de)
AU (2)	AU2005318190B2 (de)
BR (1)	BRPI0517132B8 (de)
CA (2)	CA3087419C (de)
CY (3)	CY1112614T1 (de)
DK (3)	DK2805723T3 (de)
EA (1)	EA015799B1 (de)
ES (2)	ES3007339T3 (de)
FI (1)	FI4070800T3 (de)
FR (1)	FR18C1008I2 (de)
HR (1)	HRP20120228T1 (de)
HU (3)	HUE059133T2 (de)
IL (2)	IL183930A0 (de)
LT (3)	LT4070800T (de)
LU (1)	LUC00064I2 (de)
MX (1)	MX2007007610A (de)
NO (1)	NO20073813L (de)
PL (4)	PL1827461T3 (de)
SG (1)	SG160391A1 (de)
SI (3)	SI2805723T1 (de)
WO (1)	WO2006067141A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2275110B1 (de)	2004-12-22	2013-07-10	Merck Serono SA	Cladribin Dosierschema zur Behandlung von multipler Sklerose
WO2007135172A2 (en)	2006-05-24	2007-11-29	Laboratoires Serono S.A.	Cladribine regimen for treating multiple sclerosis
EP2343074A1 (de)	2009-12-23	2011-07-13	Merck Serono S.A.	Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
WO2011117267A1 (en)	2010-03-24	2011-09-29	Merck Serono Sa	Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (de)	2010-09-08	2012-03-14	Merck Serono S.A.	Orale Verabreichung von Nukleosidmonophosphaten
WO2012097867A1 (en)	2011-01-18	2012-07-26	Synthon Bv	Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en)	2014-01-29	2014-03-12	Roach Arthur H	Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en)	2017-07-21	2019-01-23	Chord Therapeutics S A R L	Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) *	2017-11-24	2020-06-24	Merck Patent Ges Mit Beschraenkter Haftung	Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
BR112023003432A2 (pt)	2020-09-10	2023-03-21	Merck Patent Gmbh	Regime de tratamento para o tratamento de doenças autoimunes
GB2601786A (en) *	2020-12-10	2022-06-15	Chord Therapeutics S A R L	Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1269659A (en)	1984-08-06	1990-05-29	Brigham Young University	Method for the production of 2'-deoxyadenosine compounds
US5310732A (en)	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) *	1988-06-27	1990-10-23	Bloom Philip M	Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en)	1991-12-18	1993-05-04	Ortho Pharmaceutical Corporation	Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en)	1994-12-21	1997-06-24	Ortho Pharmaceutical Corporation	Stable 2-chloro-2'-deoxyadenosine formulations
EP0801571B1 (de)	1994-12-22	2002-09-04	Ortho Pharmaceutical Corporation	Lösliche arzneizusammensetzungen enthaltend 2-chloro-2'-deoxyadenosine
US6194395B1 (en)	1999-02-25	2001-02-27	Orthro-Mcneil Pharmaceutical, Inc.	Cyclodextrin cladribine formulations
WO2000064918A1 (en)	1999-04-28	2000-11-02	Sterrenbeld Biotechnologie North America, Inc.	METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) *	2002-08-13	2004-03-04	Medac Gesellschaft für klinische Spezialpräparate mbH	Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556400B1 (de)	2002-09-25	2013-05-01	Brigham Young University	Verfahren zur herstellung von 2-halogen-2-desoxyadenosinverbindungen aus 2-desoxyguanosin
GB2394658A (en) *	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
WO2004075903A1 (en) *	2003-02-25	2004-09-10	Applied Research Systems Ars Holding N.V.	Combined use of ribavirin and interferon beta in demyelinating diseases
DK2272503T3 (da)	2003-03-28	2013-05-21	Ares Trading Sa	Orale formuleringer af cladribin
WO2004087100A2 (en)	2003-03-28	2004-10-14	Ivax Corporation	Cladribine formulations for improved oral and transmucosal delivery
EP2275110B1 (de)	2004-12-22	2013-07-10	Merck Serono SA	Cladribin Dosierschema zur Behandlung von multipler Sklerose
WO2007135172A2 (en) *	2006-05-24	2007-11-29	Laboratoires Serono S.A.	Cladribine regimen for treating multiple sclerosis

2005
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/de not_active Expired - Lifetime
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/de not_active Expired - Lifetime
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/de not_active Revoked
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/de not_active Expired - Lifetime
- 2005-12-20 EP EP05823474A patent/EP1827461B1/de not_active Expired - Lifetime
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/de not_active Revoked
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/de not_active Withdrawn
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending

Also Published As

Publication number	Publication date
LUC00064I1 (de)	2018-02-14
EP4070800A1 (de)	2022-10-12
IL212421A (en)	2014-01-30
EP2805723A1 (de)	2014-11-26
EP2275110A2 (de)	2011-01-19
FR18C1008I1 (de)	2018-03-30
JP2020193206A (ja)	2020-12-03
JP2016138128A (ja)	2016-08-04
JP5795456B2 (ja)	2015-10-14
EP2805723B1 (de)	2018-01-17
IL183930A0 (en)	2007-10-31
HUE059133T2 (hu)	2022-10-28
EP2275110B1 (de)	2013-07-10
JP5908863B2 (ja)	2016-04-26
PL3332789T3 (pl)	2022-08-22
JP6290962B2 (ja)	2018-03-07
EP2275110A3 (de)	2011-04-27
JP6092945B2 (ja)	2017-03-08
HRP20120228T1 (hr)	2012-04-30
ES3007339T3 (en)	2025-03-19
CY2018006I1 (el)	2018-06-27
CY2018006I2 (el)	2018-06-27
ES2921858T3 (es)	2022-09-01
LT4070800T (lt)	2025-01-10
EP4523753A2 (de)	2025-03-19
SG160391A1 (en)	2010-04-29
EP4070800B1 (de)	2024-10-16
PL1827461T3 (pl)	2012-07-31
AU2005318190B2 (en)	2010-11-25
US8377903B2 (en)	2013-02-19
EP3332789A1 (de)	2018-06-13
EP2263678A2 (de)	2010-12-22
AU2005318190A1 (en)	2006-06-29
CA3087419C (en)	2023-03-07
LTC2805723I2 (lt)	2022-04-25
EP2263678B1 (de)	2014-06-11
BRPI0517132B1 (pt)	2020-02-18
DK3332789T3 (da)	2022-07-11
DK4070800T3 (da)	2025-01-02
JP6430554B2 (ja)	2018-11-28
EA015799B1 (ru)	2011-12-30
CA2588966A1 (en)	2006-06-29
US20100203017A1 (en)	2010-08-12
PL2805723T3 (pl)	2018-04-30
EP1827461B1 (de)	2012-02-29
LT3332789T (lt)	2022-07-25
EA200701221A1 (ru)	2008-02-28
CY1119790T1 (el)	2018-06-27
CY1112614T1 (el)	2016-02-10
EP2263678A3 (de)	2011-04-27
CA3087419A1 (en)	2006-06-29
WO2006067141A1 (en)	2006-06-29
AU2011200768B2 (en)	2012-09-13
NO20073813L (no)	2007-09-21
JP2017101061A (ja)	2017-06-08
HUS1800009I1 (hu)	2018-05-02
SI3332789T1 (sl)	2022-08-31
MX2007007610A (es)	2007-08-03
KR20070091662A (ko)	2007-09-11
DK2805723T3 (da)	2018-01-29
EP3332789B1 (de)	2022-04-06
JP2008524313A (ja)	2008-07-10
EP4523753A3 (de)	2025-05-28
EP1827461A1 (de)	2007-09-05
US20090081163A1 (en)	2009-03-26
JP2015180685A (ja)	2015-10-15
JP2018165271A (ja)	2018-10-25
US7713947B2 (en)	2010-05-11
IL212421A0 (en)	2011-06-30
JP2013216664A (ja)	2013-10-24
BRPI0517132A (pt)	2008-09-30
HUE070333T2 (hu)	2025-05-28
LUC00064I2 (de)	2018-03-28
SI2805723T1 (en)	2018-02-28
BRPI0517132B8 (pt)	2021-05-25
FI4070800T3 (fi)	2025-01-14
SI4070800T1 (sl)	2025-03-31
AR052830A1 (es)	2007-04-04
LTPA2018503I1 (lt)	2018-03-12
CA2588966C (en)	2020-07-21
AU2011200768A1 (en)	2011-03-17
PL4070800T3 (pl)	2025-03-10

Publication	Publication Date	Title
FR18C1008I2 (fr)	2019-03-01	Regime posologique de cladribine pour le traitement de la sclerose en plaques
FR23C1003I2 (fr)	2024-01-12	Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
EP2059210A4 (de)	2013-01-09	Therapeutische vorrichtungen zur behandlung verschiedener frauenleiden
EP1931691A4 (de)	2012-01-11	Odkase-inhibitoren zur behandlung von malaria
EP1773226A4 (de)	2008-03-26	Energievorrichtungen zur behandlung von anatomischen defekten
EP1838320A4 (de)	2009-03-18	Cxcr4-antagonisten zur behandlung medizinischer probleme
EP1951272A4 (de)	2010-01-27	Verwendung von lactobacillus zur behandlung von virusinfektionen
EP1985302A4 (de)	2013-01-02	Arzneimittel zur tumortherapie und seine verwendung
EP2313146A4 (de)	2015-07-08	Vorrichtungen zur behandlung von vaskulärem aneurysma
EP2773643A4 (de)	2015-07-29	Pak-hemmer zur behandlung von fragilem-x-syndrom
EP2442832A4 (de)	2013-07-03	Zusammensetzungen und verfahren zur behandlung von multipler sklerose
PL2205720T3 (pl)	2017-06-30	Kompozycja do leczenia stwardnienia rozsianego
EP2207892A4 (de)	2010-12-08	Verfahren zur selektion aktiver agentien für die krebsbehandlung
EP2144632A4 (de)	2010-08-25	Synthetische herpes-simplex-viren typ 1 zur tumorbehandlung
EP1789069A4 (de)	2011-01-26	Cyclische peptide zur behandlung von kachexie
FR2962041B1 (fr)	2012-07-27	Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies
EP2389180A4 (de)	2012-08-15	Verfahren zur behandlung von muskeldystrophien
EP1773970A4 (de)	2010-08-11	Schmiermittelformulierungen für die blechverarbeitung
FR2907011B1 (fr)	2010-05-14	Utilisation de la citrulline pour le traitement des etats de denutrition
EP2015741A4 (de)	2009-12-23	Histondeacetylase-hemmer zur behandlung von neurodegeneration
EP1832861A4 (de)	2013-01-23	Komponente zur voranalytischen behandlung
EP1732549A4 (de)	2009-11-11	Verfahren zur behandlung von synucleinopathien
EP1889618A4 (de)	2010-11-24	Kombiniertes arzneimittel zur behandlung von diabetes
FR2886153B1 (fr)	2009-04-10	Composition destinee au traitement de la sclerose en plaques
EP2099303A4 (de)	2010-11-10	Therapeutische zusammensetzungen auf tetrahydroisochinolinbasis für krebstherapie